Logo

Dharmacon, Wellcome Trust Sanger Institute

Dec 23, 2005
Premium

Dharmacon has recently introduced the miRidian microRNA inhibitors and mimics.

According to the company, the inhibitors and mimics are based on known or predicted miRNA sequences for human, mouse and rat as defined in the Wellcome Trust Sanger Institute's miRBase.

MiRNA inhibitors facilitate loss-of-function studies, while miRNA mimics may be useful for gain-of function studies, Dharmacon said.

NOTE: This is the last issue of RNAi News to be published in 2005. We will resume our normal publishing schedule on Jan. 6, 2006.

Filed under

Gene Silencing/Gene Editing
RNAi
Breaking News
The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.